Strategic partnerships Nanomerics collaborates with external pharma players, including a NASDAQ company for oral products and an Asian partner for nasal delivery, indicating a readiness to co-develop and license programs. This suggests sales opportunities in collaborative development, licensing, and co-commercialization arrangements with multinational partners seeking nanotechnology-enabled drug delivery.

Nanotechnology moat With Molecular Envelope Technology enabling oral, nasal, ocular, and blood-brain barrier delivery for a range of compounds, Nanomerics can position itself as a specialist in formulating difficult-to-deliver APIs. Sales opportunities exist in upgrading existing drug portfolios that suffer from poor solubility, bioavailability, or delivery challenges.

Lead product potential Lead peptide for chronic pain leverages the endogenous peptide's safety and efficacy with MET to mitigate opioid-related issues. This presents a compelling value proposition for stakeholders in pain management and opioid-sparing strategies, opening doors to partnerships or licensing deals around analgesic candidates.

Diversified targets Company has activity in ophthalmic and oral oncology areas, plus prior nasal and CNS delivery programs. This breadth allows cross-portfolio cross-selling with partners seeking multiple delivery modalities or pipeline diversification, and enables targeted outreach to ophthalmology, CNS, and oncology segments.

Recognition and visibility Recent King’s Award for Enterprise in Innovation elevates credibility and visibility in the UK and beyond. This accolade can be leveraged in business development pitches to establish trust with potential licensors, partners, and investors looking for award-winning biotech collaborators.